LGD-4033 vs RAD-140: SARM Comparison for Research

LGD-4033 (Ligandrol) shows higher anabolic potency in preclinical skeletal muscle assays and maintains a dose-proportional response curve that RAD-140 does not. RAD-140 (Testolone) exhibits tissue-selective androgenic activity with less suppression of endogenous testosterone in rodent models, but its potency ceiling is lower. The choice depends on whether the research goal prioritizes maximal lean mass response or minimized hormonal disruption.

Quick Comparison

How LGD-4033 Binds and Why Its Dose Response Is Linear

LGD-4033 is a non-steroidal androgen receptor ligand with an EC50 of approximately 1 nM in cell-based reporter assays. It binds the AR ligand-binding domain with high affinity but recruits coactivator proteins differentially across tissues. In human Phase I trials, researchers observed dose-proportional increases in lean body mass from 0.1 mg to 1.0 mg daily over 21 days. At the 1.0 mg dose, subjects gained an average of 1.21 kg lean mass versus placebo, with suppression of total testosterone to approximately 40% of baseline. The dose-response curve remained linear without plateau effects, suggesting the therapeutic ceiling was not reached in these trials.

The tissue selectivity comes from conformational changes in the AR ligand-binding domain upon LGD-4033 binding. These changes favor recruitment of coactivators in muscle but not in prostate tissue, where the AR remains a partial agonist. This explains the 10:1 anabolic-to-androgenic ratio seen in rat levator ani versus ventral prostate assays. The mechanism is not total AR sparing in androgenic tissues—it is incomplete activation.

LGD-4033's 24-36 hour half-life permits once-daily dosing in research protocols. Steady-state concentrations are reached by day 5. This pharmacokinetic profile makes it the more predictable compound for sustained AR stimulation studies.

How RAD-140 Achieves Tissue Selectivity and Where It Fails to Scale

RAD-140 binds the androgen receptor with similar affinity to LGD-4033, but its selectivity profile differs mechanistically. In rodent castration models, RAD-140 at 0.1 mg/kg maintained levator ani muscle mass without significant prostate weight increase. The proposed mechanism involves differential recruitment of SRC-1 and SRC-3 coactivators. In muscle tissue, RAD-140-bound AR recruits SRC-1 efficiently; in prostate, recruitment is reduced.

The compound also demonstrates preferential AR binding in the hippocampus and cortex, which has made it a candidate for neuroprotection studies. In a rat model of traumatic brain injury, RAD-140 at 1 mg/kg daily reduced apoptosis in the dentate gyrus by approximately 40% versus vehicle. This CNS activity is not observed with LGD-4033.

However, RAD-140's anabolic response does not scale linearly with dose in the way LGD-4033 does. In rat studies, doses above 0.3 mg/kg showed diminishing returns on lean mass accrual, suggesting receptor saturation or compensatory downregulation. No human pharmacokinetic data has been published, and the compound remains in the preclinical phase. This evidence gap limits its use in translational research where human relevance must be inferred.

Where Their Effects Overlap and Why Stacking Adds Little

Both compounds are full agonists at the androgen receptor in skeletal muscle. They increase muscle protein synthesis through the same AR-mediated signaling cascade: AR binding, translocation to the nucleus, DNA binding at androgen response elements, and transcription of myogenic genes. Both suppress luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through negative feedback at the hypothalamic-pituitary axis. In human trials of LGD-4033, LH suppression was dose-dependent and reversed within 4 weeks of cessation.

Because both compounds act on the same receptor, stacking them does not produce additive anabolic effects—it produces competitive inhibition. The compound with higher affinity (they are similar) will dominate receptor occupancy. The only theoretical advantage of stacking would be if one compound's tissue distribution compensated for the other's, but both are lipophilic small molecules with similar pharmacokinetics. No published data supports synergistic effects.

The overlapping suppression of endogenous testosterone means combining them doubles the suppressive load without doubling the anabolic signal. For research purposes only, stacking these two compounds is mechanistically redundant.

The Practical Difference: When LGD-4033's Potency Beats RAD-140's Selectivity

LGD-4033 is the stronger choice when the research question centers on maximal anabolic response or dose-response characterization. Its linear dose-response curve and human safety data make it viable for studies modeling muscle protein synthesis, cachexia interventions, or anabolic threshold determination. The Phase I data provides a validated dosing range (0.1-1.0 mg) and known suppression profile, which RAD-140 lacks.

RAD-140 is the better choice when the goal is androgen receptor research with minimal prostate involvement or when exploring neuroprotective AR pathways. Its higher selectivity ratio in prostate tissue and demonstrated CNS AR activity make it suitable for brain-muscle crosstalk studies or models where endogenous testosterone suppression must be minimized. However, the absence of human PK data means dose extrapolation from rodent studies is speculative.

In head-to-head rodent studies, LGD-4033 consistently produces greater lean mass gain at equivalent receptor occupancy. A study comparing 0.5 mg/kg LGD-4033 to 0.5 mg/kg RAD-140 in castrated male rats showed LGD-4033 restored 88% of levator ani weight versus 72% for RAD-140 after 28 days. Both compounds suppressed prostate weight to approximately 15% of intact controls.

The decision is not subtle: LGD-4033 for anabolic magnitude, RAD-140 for tissue selectivity or CNS involvement.

FAQ

Q: Does RAD-140 suppress testosterone less than LGD-4033?

In rodent castration models, RAD-140 showed less dose-dependent suppression of LH at equivalent AR occupancy. However, no controlled human trials exist for RAD-140. LGD-4033's Phase I data shows clear dose-dependent suppression: at 1.0 mg/day, total testosterone dropped to ~40% baseline and recovered within 4 weeks post-cessation. Until RAD-140 undergoes Phase I trials, the suppression comparison in humans remains speculative.

Q: Can these compounds be used in the same protocol at different times?

Yes, in sequential dosing protocols where washout prevents receptor cross-competition. LGD-4033's 24-36 hour half-life requires approximately 5 half-lives (5-7 days) to clear 97% of circulating compound. RAD-140's shorter half-life suggests 3-4 days. Sequential use allows comparison of each compound's isolated effect without confounding receptor occupancy overlap.

Q: Which compound has better oral bioavailability?

LGD-4033 demonstrated 100% oral bioavailability in rat PK studies and maintained consistent plasma levels in human Phase I trials. RAD-140's bioavailability in rodents exceeds 80%, but human data is not published. Both are orally active and do not require esterification or injection.

Q: What is the evidence quality gap between these two compounds?

LGD-4033 has completed Phase I human safety trials (NCT01355497) with published data on 76 subjects, including dose escalation, PK/PD modeling, and hormonal suppression kinetics. Phase II trials for muscle wasting are ongoing. RAD-140 has no published Phase I data and remains limited to rodent and cell culture studies. The evidence gap is substantial—LGD-4033 has crossed into human validation; RAD-140 has not.

Q: Do these compounds affect lipid profiles differently?

In LGD-4033's Phase I trial, HDL cholesterol decreased by approximately 40% at the 1.0 mg dose, while LDL remained stable. Triglycerides increased modestly. RAD-140 showed similar HDL suppression in rodent models, but the magnitude and reversibility in humans is unknown. Both compounds likely affect lipid metabolism through AR-mediated hepatic gene expression, but only LGD-4033 has human lipid data.

---

The information presented here is intended for educational and research purposes only. SARMs including LGD-4033 and RAD-140 are not approved for human use by any regulatory authority and are not intended for the diagnosis, treatment, cure, or prevention of any disease. Always consult appropriate scientific literature and institutional review protocols before conducting research with these compounds.